Risk of Post-SSRI Sexual Dysfunction: A Retrospective Study
Antidepressants linked to higher ED risk and rare PSSD; study underscores need for informed consent.
A recent retrospective cohort study has shed light on the small but significant risk of Post-SSRI Sexual Dysfunction (PSSD) in males treated with serotonergic antidepressants (SAs). Conducted over 19 years, the study involved 12,302 males and aimed to assess the likelihood of developing erectile dysfunction (ED) and PSSD following SA treatment.
The results show that males treated with SAs have a more than threefold increased risk of ED, with 0.46% developing PSSD. This finding highlights the need for open communication about the potential long-term sexual side effects of antidepressants.
While PSSD is rare, its implications are serious, making it crucial for healthcare providers to discuss these risks with patients before prescribing serotonergic antidepressants.
Read the full study here.
This information does not replace medical advice. Talk to your doctor before you make any decision about your treatment.
570+ people have joined the registry.
Join them, then report your side effects.
- Put your condition on the record
- Be first to hear about studies you can join
- Then report your side effects to your regulator